Monthly Archives: March 2013

Aurora BioScience Pty. Ltd. today announced that it has launched the dermaPACE wound healing system

By Aurora BioScience Dated: Mar 18th 2013

dermaPACE – Advanced Wound Healing Technology.

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has launched the dermaPACE wound healing system.

The dermaPACE system from Sanuwave Health, utilises Pulsed Acoustic Cellular Expression (PACE®) technology, or high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures to elicit a series of biological responses. PACE® treatment results in an increase in perfusion and arteriogenesis, biofilm disruption, a pro-inflammatory response, cytokine and chemokine effects, growth factor up-regulation, angiogenesis (new blood vessel formation) and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures.

Aurora BioScience entered into an exclusive distribution agreement with Sanuwave Health in 2012 and received Therapeutic Goods Administration (TGA) approval in March 2013. Under the agreement Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution in both the Australian and New Zealand markets.

“The dermaPACE system really is an exciting new development for the treatment of wounds, especially chronic, difficult to treat wounds.” said Darren Banks, Managing Director of Aurora BioScience. “ Both Sanuwave and Aurora believe in the potential for PACE® technology to positively impact patients whose lives suffer from debilitating wounds and injuries.”

The dermaPACE system is designed to provide extracorporeal shock wave therapy (ESWT) intended to treat acute and chronic conditions of the skin and subcutaneous soft tissues (eg, arterial, venous, diabetic or pressure ulcers, burns, postoperative or traumatic wounds).

“We are excited to be partnering with such an innovative company as Sanuwave Health and believe that the dermaPACE device can assist healthcare professionals provide improved patient outcomes. We are expecting the first procedures to be undertaken in Australia in late March with many hospitals and clinics extremely keen to evaluate the product” stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include wound healing, cancer therapies, neurology, pulmonology, haematology and blood products. For more information, please visit www.aurorabioscience.com.au

About Sanuwave

SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including revascularization and microcirculatory improvement, helping restore the body’s normal healing processes and regeneration. SANUWAVE is applying its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Headquartered in Alpharetta, GA, SANUWAVE designs, manufactures, markets, and services its industry leading products worldwide.

http://sanuwave.com/international/dermapace/